Clinical trials show retatrutide, Eli Lilly's new triple-agonist drug, delivered 24.2% weight loss in 48 weeks and the ...

The discussion surrounding GLP-1 medications needs to change to one that emphasizes science-based research and compassion.

A new RAND report shows nearly 12% of U.S. adults now use GLP-1 drugs like Ozempic and Wegovy, and it’s changing how they shop. Food companies say the biggest shift isn’t in portion sizes but in the ...

Learn how GLP-1 medications support weight loss and heart health in perimenopause and postmenopause, plus get tips for ...

Friendly” labels on the packaging are becoming more common in U.S. supermarkets as a growing number of Americans try obesity ...

GLP-1s are used for type 2 diabetes, as well as weight loss in people with obesity or overweight with a related health condition. Read on for everything you need to know about GLP-1s for weight loss, ...

Discover the top five ingredient trends driving GLP-1 innovation in the food and beverage industry. From proteins and fibers ...

GLP-1 weight-loss drugs have already seen massive success in the US. While they've made some headway into the European market ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) like semaglutide and liraglutide mimic endogenous incretin signals to stimulate glucose-dependent insulin release, thereby suppressing glucagon, ...

In a new trial, people who switched to the experimental daily GLP-1 pill orforglipron were able to keep off most of the weight they had lost taking Wegovy or Zepbound. People who switched from Wegovy ...

Brooke Boyarsky Pratt, CEO, and Dr. Angela Fitch, chief medical officer, are both co-founders of knownwell. More than 12% of U.S. adults now take a GLP-1 medication, marking one of the ...

GLP-1s for weight loss may not affect the risk of obesity-related cancers either way, an analysis of the existing evidence suggests.